Discovery of Small-Molecule Ras Inhibitors that Display Antitumor Activity by Interfering with Ras·GTP-Effector Interaction

Enzymes

Volumn 34, Issue , 2013, Pages 1-23

  Shima, Fumi ^a   Yoshikawa, Yoko ^a   Matsumoto, Shigeyuki ^a   Kataoka, Tohru ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Antitumor activity; Computer docking simulation; NMR; Ras inhibitor; Structure based drug design; X ray crystallography

Indexed keywords

ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; GUANOSINE TRIPHOSPHATE; RAS PROTEIN;

ANIMAL; ANTINEOPLASTIC ACTIVITY; ARTICLE; COMPUTER DOCKING SIMULATION; DRUG ANTAGONISM; DRUG DEVELOPMENT; HUMAN; METABOLISM; MOLECULAR LIBRARY; NEOPLASM; NUCLEAR MAGNETIC RESONANCE; RAS INHIBITOR; STRUCTURE-BASED DRUG DESIGN; X-RAY CRYSTALLOGRAPHY;

ANTITUMOR ACTIVITY; COMPUTER DOCKING SIMULATION; NMR; RAS INHIBITOR; STRUCTURE-BASED DRUG DESIGN; X-RAY CRYSTALLOGRAPHY;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DISCOVERY; ENZYME INHIBITORS; GUANOSINE TRIPHOSPHATE; HUMANS; NEOPLASMS; RAS PROTEINS; SMALL MOLECULE LIBRARIES;

EID: 84887226660     PISSN: 18746047     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-420146-0.00001-9     Document Type: Chapter

References (36)

1. Karnoub A.E., Weinberg R.A. Ras oncogenes: split personalities. Nat. Rev. Mol. Cell Biol. 2008, 9(7):517-531.
2. Vetter I.R., Wittinghofer A. The guanine nucleotide-binding switch in three dimensions. Science 2001, 294(5545):1299-1304.
3. Weinstein B. Cancer. Addiction to oncogenes-the Achilles heal of cancer. Science 2002, 297(5578):63-64.
4. Chin L., et al. Essential role for oncogenic Ras in tumour maintenance. Nature 1999, 400(6743):468-472.
5. Podsypanina K., Politi K., Beverly L.J., Varmus H.E. Oncogene cooperation in tumor maintenance and tumor recurrence in mouse mammary tumors induced by Myc and mutant Kras. Proc. Natl. Acad. Sci. U.S.A. 2008, 105(13):5242-5247.
6. James G.L., Goldstein J.L., Brown M.S. Polylysine and CVIM sequences of K-RasB dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetic in vitro. J. Biol. Chem. 1995, 270(11):6221-6226.
7. Rotblat B., Ehrlich M., Haklai R., Kloog Y. The Ras inhibitor farnesylthiosalicylic acid (Salirasib) disrupts the spatiotemporal localization of active Ras: a potential treatment for cancer. Methods Enzymol. 2008, 439:467-489.
8. Pai E.F., et al. Structure of the guanine-nucleotide-binding domain of the Ha-ras oncogene product p21 in the triphosphate conformation. Nature 1989, 341(6239):209-214.
9. Ye M., et al. Crystal structure of M-Ras reveals a GTP-bound "off" state conformation of Ras family small GTPases. J. Biol. Chem. 2005, 280(35):31267-31275.
10. Shima F., et al. Structural basis for conformational dynamics of GTP-bound Ras protein. J. Biol. Chem. 2010, 285(29):22696-22705.
11. Araki M., et al. Solution structure of the state 1 conformer of GTP-bound H-Ras protein and distinct dynamic properties between the state 1 and state 2 conformers. J. Biol. Chem. 2011, 286(45):39644-39653.
12. Muraoka S., et al. Crystal structures of the state 1 conformations of the GTP-bound H-Ras protein and its oncogenic G12V and Q61L mutants. FEBS Lett. 2012, 586(12):1715-1718.
13. Sitkoff D., Sharp K.A., Honig B. Accurate calculation of hydration free energies using macroscopic solvent models. J. Phys. Chem. 1994, 98(7):1978-1988.
14. Fukunishi Y., Mikami Y., Nakamura H. The filling potential method: a method for estimating the free energy surface for protein-ligand docking. J. Phys. Chem. B 2003, 107(47):13201-13210.
15. Fukunishi Y., Mikami Y., Nakamura H. Similarities among receptor pockets and among compounds: analysis and application to in silico ligand screening. J. Mol. Graph. Model. 2005, 24(1):34-45.
16. Shima F., et al. In silico discovery of small-molecule Ras inhibitors that display antitumor activity by blocking the Ras-effector interaction. Proc. Natl. Acad. Sci. U.S.A. 2013, 110(20):8182-8187.
17. Willett P., Barnard J.M., Downs G.M. Chemical similarity searching. J. Chem. Inf. Comput. Sci. 1998, 38(6):983-996.
18. Wilhelm S., et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat. Rev. Drug Discov. 2006, 5(10):835-844.
19. Margarit S.M., et al. Structural evidence for feedback activation by Ras-GTP of the Ras-specific nucleotide exchange factor SOS. Cell 2003, 112(5):685-695.
20. Wang G.M., et al. Single copies of mutant K-ras and mutant PIK3CA cooperate in immortalized human epithelial cells to induce tumor formation. Cancer Res. 2013, 73(11):3248-3261.
21. Ito Y., et al. Regional polysterism in the GTP-bound form of the human c-Ha-Ras protein. Biochemistry 1997, 36(30):9109-9119.
22. Nassar N., et al. The 2.2 Å crystal structure of the Ras-binding domain of the serine/threonine kinase c-Raf1 in complex with Rap1A and a GTP analogue. Nature 1995, 375(6532):554-560.
23. Pacold M.E., et al. Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase gamma. Cell 2000, 103(6):931-943.
24. Huang L., Hofer F., Martin G.S., Kim S.H. Structural basis for the interaction of Ras with RalGDS. Nat. Struct. Biol. 1998, 5(6):422-426.
25. Hajduk P.J., Olejniczak E.T., Fesik S.W. One-dimensional relaxation- and diffusion-edited NMR methods for screening compounds that bind to macromolecules. J. Am. Chem. Soc. 1997, 119(50):12257-12261.
26. Geyer M., et al. Conformational transitions in p21ras and in its complexes with the effector protein Raf-RBD and the GTPase activating protein GAP. Biochemistry 1996, 35(32):10308-10320.
27. Geyer M., et al. Conformational states of the nuclear GTP-binding protein Ran and its complexes with the exchange factor RCC1 and the effector protein RanBP1. Biochemistry 1999, 38(35):11250-11260.
28. Spoerner M., et al. Slow conformational dynamics of the guanine nucleotide-binding protein Ras complexed with the GTP analogue GTPγS. FEBS J. 2007, 274(6):1419-1433.
29. Liao J., et al. Two conformational states of Ras GTPase exhibit differential GTP-binding kinetics. Biochem. Biophys. Res. Commun. 2008, 369(2):327-332.
30. Fenwick R.B., et al. Solution structure and dynamics of the small GTPase RalB in its active conformation: significance for effector protein binding. Biochemistry 2009, 48(10):2192-2206.
31. 17O labeling of threonine. Biochemistry 1996, 35(37):12194-12200.
32. Matsumoto K., et al. Critical roles of interactions among switch I-preceding residues and between switch II and its neighboring a-helix in conformational dynamics of the GTP-bound Ras family small GTPases. J. Biol. Chem. 2011, 286(17):15403-15412.
33. Maurer T., et al. Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity. Proc. Natl. Acad. Sci. U.S.A. 2012, 109(14):5299-5304.
34. Sun Q., et al. Discovery of small molecules that bind to K-Ras and inhibit Sos-mediated activation. Angew. Chem. Int. Ed. Engl. 2012, 51(25):6140-6143.
35. Hocker H.J., et al. Andrographolide derivatives inhibit guanine nucleotide exchange and abrogate oncogenic Ras function. Proc. Natl. Acad. Sci. U.S.A. 2013, 110(25):10201-10206.
36. Lim K.H., Ancrile B.B., Kashatus D.F., Counter C.M. Tumor maintenance is mediated by eNOS. Nature 2008, 452(7187):646-649.